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Abstract
Introduction Covid-19 infection poses a serious challenge for immune-compromised patients with inflammatory autoimmune
systemic diseases. We investigated the clinical-epidemiological findings of 1641 autoimmune systemic disease Italian patients
during the Covid-19 pandemic.
Method This observational multicenter study included 1641 unselected patients with autoimmune systemic diseases from three
Italian geographical areas with different prevalence of Covid-19 [high in north (Emilia Romagna), medium in central (Tuscany),
and low in south (Calabria)] by means of telephone 6-week survey. Covid-19 was classified as (1) definite diagnosis of Covid-19
disease: presence of symptomatic Covid-19 infection, confirmed by positive oral/nasopharyngeal swabs; (2) highly suspected
Covid-19 disease: presence of highly suggestive symptoms, in absence of a swab test.
Results A significantly higher prevalence of patients with definite diagnosis of Covid-19 disease, or with highly suspectedCovid-
19 disease, or both the conditions together, was observed in the whole autoimmune systemic disease series, compared to “Italian
general population” (p = .030, p = .001, p = .000, respectively); and for definite + highly suspected diagnosis of Covid-19 disease,
in patients with autoimmune systemic diseases of the three regions (p = .000, for all comparisons with the respective regional
general population).Moreover, significantly higher prevalence of definite + highly suspected diagnosis of Covid-19 disease was
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patients without ongoing conventional synthetic disease-modifying anti-rheumatic drugs treatments (p = .011).
Conclusions The finding of a higher prevalence of Covid-19 in patients with autoimmune systemic diseases is particularly
important, suggesting the need to develop valuable prevention/management strategies, and stimulates in-depth investigations
to verify the possible interactions between Covid-19 infection and impaired immune-system of autoimmune systemic diseases.
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Introduction
The recent outbreak due to a newly identified β-coronavirus
(Covid-19, or SARS-CoV-2) spreads worldwide (today,
May 21, 2020); > 5,000,000 cases are reported, and the num-
ber is increasing every day. About 30–70% of infected pa-
tients are asymptomatic (asymptom-covid-19); however, 20–
50% need hospitalization [1, 2].
Within the subset of Covid-19 symptomatic patients (sympt-
Covid-19) admitted to hospital, the most common symptoms at
onset of illness were fever, cough, dyspnea, myalgia, or fatigue.
Notably, 20–30% of sympt-Covid-19 had upper respiratory tract
symptoms such as coryza or other symptoms such as nausea,
vomiting, diarrhea, dysgeusia, and anosmia. About 20–30% of
hospitalized patients required intensive care unit admission for
respiratory support; among them, 70–80% of patients were male,
older than 65 years, and 30–50% had pre-existing comorbidities,
such as hypertension (15–25%), diabetes (20–25%), obesity, and
cardiovascular diseases (10–15%), or chronic obstructive pulmo-
nary disease (10–15%) [2–6]. On the whole, increased risk to
worse Covid-19 disease outcomes may be observed in immune-
compromised patients [6–9]. Therefore, Covid-19 pandemic in-
fection poses a serious challenge for the management of patients
with “inflammatory autoimmune systemic diseases” (ASD). In
fact, ASD patients represent a vast population of tens of millions
of patients worldwide with compromised immune system and
increased susceptibility to different types of viral and bacterial
infections, frequently aggravated by ongoing immune modifier
treatments [6–9].
On the other side, several anecdotal observations and co-
hort studies of ASD patients suggested the potential
therapeutic role of some anti-rheumatic immune-modulating
drugs (such as hydroxychloroquine and tocilizumab), which
may potentially interfere with viral infection or the cytokine
storm syndrome observed in Covid-19 in association with
severe acute respiratory distress syndrome. Therefore, the
immune-compromised condition along with the frequent ad-
ministration of immune-suppressive treatments in ASD pa-
tients might prevent them from Covid-19 major complications
[8, 10–13].
These apparently conflicting assumptions may be clar-
ified by epidemiological studies on the actual incidence
of Covid-19 in ASD patients, as well as by the results of
ongoing trials on various anti-inflammatory/immune-
modulating therapies in patients with Covid-19 [8,
10–15].
At the beginning of March 2020, the rapid diffusion of
pandemic Covid-19 has induced the Italian government to
take stringent measures aimed at slowing the spread of the
virus. The restrictions on individual movement have compro-
mised the regular face-to-face activities of outpatient clinics,
mainly required for the tight monitoring of ASD patients un-
dergoing immune-modulating treatments; the same restric-
tions also prevented the timely detection of symptoms sugges-
tive of Covid-19 disease. In this context, we organized a mul-
ticenter telephone survey study aiming to identify subjects
with overt/suspected Covid-19 disease in a large ASD patient
population.
Here, we report the epidemiological and clinical findings,
observed in our ASD patients during the 6-week survey period
coincident with the most critical phase of pandemic Covid-19
in Italy.
Key Points
• Significantly higher prevalence of Covid-19 is observed in a large series of patients with autoimmune systemic diseases compared to the Italian general
population, mainly due to patients’ increased susceptibility to infections and favored by the high exposure to the virus at medical facilities before the
restriction measures on individual movement.
• The actual prevalence of Covid-19 in autoimmune systemic diseases may be underestimated, possibly due to the wide clinical overlapping between the
two conditions, the generally mild Covid-19 disease manifestations, and the limited availability of virological testing.
• Patients with “connective tissue diseases” show a significantly higher prevalence of Covid-19, possibly due to deeper immune-system impairment, with
respect to “inflammatory arthritis group”.
• Covid-19 is more frequent in the subgroup of autoimmune systemic diseases patients without ongoing conventional synthetic disease-modifying
anti-rheumatic drugs, mainly hydroxyl-chloroquine and methotrexate, which might play some protective role against the most harmful manifestations
of Covid-19.
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Patients and methods
The present observational multicenter cohort study aimed to
investigate the prevalence of Covid-19 infection in a large
series of ASD Italian patients, resident in three geographical
areas of Italy, with different prevalence of Covid-19 infection
(high prevalence in north, medium in central, and low in
south, Italy), by means of a telephone 6-week survey (from
March 15th, to April 25th) in order to evaluate the cumulative
prevalence from January 2020 of overt/suspected Covid-19
disease in ASD.
Table 1 summarizes the main characteristics of ASD pa-
tients followed at the 13 tertiary referral centers of three re-
gions of northern (Emilia Romagna), central (Tuscany), and
southern (Calabria) Italy. A total of 1641 unselected ASD
patients (F 1256, M 385, mean age 59.7 ± 13.2 years, mean
disease duration 11.5 ± 8.3 years) were consecutively en-
rolled. The classification and clinical assessment of various
ASD diseases were carried out by means of current interna-
tional criteria [16]. Clinical-epidemiological and laboratory
features, including comorbidities (obesity, hypertension, dia-
betes, renal, pulmonary, and cardiovascular involvement),
were obtained from individual records of ASD patients. In
addition, the following information were carefully collected
by trained physicians during the telephone interview accord-
ing to standardized symptom-assessment questionnaire:
(1) updating of ASD clinical features, disease activity, and
ongoing treatments of underlying comorbidities;
(2) presence and duration of any signs/symptoms [fever
(temperature > 99 °F), cough, dyspnea, myalgia, arthral-
gia, fatigue, coryza, nausea, vomiting, headache,






































Total 1641 1256/385 60 ± 13 11 ± 8 45/1641 5 95 57 62 53 4 30
Rheumatoid
arthritis
695 518/177 63 ± 13 12 ± 8 5/695 4 96 86 74 53 8 5
Psoriatic
arthritis
208 124/84 56 ± 11 11 ± 8 6/208 3 97 19 69 93 2 3
Ankylosing
spondylitis
35 10/25 50 ± 13 11 ± 9 0/35 3 97 20 37 69 - 9
Systemic
sclerosis




76 71/5 48 ± 14 15 ± 10 6/76 18 82 74 71 13 3 22
UCTD 64 60/4 55 ± 12 11 ± 8 4/64 9 92 50 80 5 - 5
PM/DM 19 14/5 61 ± 13 8 ± 10 3/19 10 89 68 47 21 - 79
Sjögren
syndrome
18 18/0 69 ± 14 12 ± 9 1/18 17 83 78 78 6 - 11
Miscellanye 88 57/31 56 ± 14 13 ± 9 2/88 16 84 84 74 75 3 48
ASD autoimmune systemic diseases, csDMARD conventional synthetic disease-modifying anti-rheumatic drugs (hydroxychloroquine, chloroquine,
methotrexate, leflunomide, sulfasalazine, cyclosporine), bDMARD biological disease-modifying antirheumatic drugs (infliximab, adalimumab,
etanercept, abatacept, tocilizumab, rituximab, anakinra, belimumab, canakinumab, certolizumab, golimumab, ixekizumab, sarilumab, secukinumab,
ustekinumab, denosumab, apremilast), tsDMARD targeted synthetic disease-modifying anti-rheumatic drugs (tofacitinib, baricitinib), UCTD undiffer-
entiated connective tissue diseases, PM/DM polymyositis/dermatomyositis
a Low dose (≤ 5 mg/day prednisone equivalent), non-steroidal anti-inflammatory drugs, and/or analgesics
b > 5 mg/day prednisone equivalent
c Other drugs: azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, IVIGs; vasoactive drugs (particularly for systemic sclerosis pts):
iloprost, bosentan, macitentan, pilocarpine, selexipag, sildenafil, tadalafil, PGE, low dose aspirin
d High-dose steroids, csDMARD, bDMARD, tsDMARD, and/or others
eMixed connective tissue disease, Behçet’s disease, idiopathic juvenile arthritis, enteropathic arthritis, sarcoidosis, polymyalgia rheumatica, systemic
vasculitis, undifferentiated inflammatory arthritis
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diarrhea, dysgeusia, anosmia] of Covid-19 disease that
had appeared within the last 2 months;
(3) sudden worsening of pre-existing manifestations such as
arthralgia, myalgia, fatigue, fever, skin lesions, and re-
spiratory symptoms (i.e., cough and dyspnea) possibly
due to ASD-related interstitial lung involvement;
(4) results (if any) of oral/nasopharyngeal swabs for Covid-
19 infection at polymerase-chain-reaction testing.
Subjects experiencing any symptom variations were invit-
ed to contact directly the interviewing physicians, after the
call.
On these bases, Covid-19 was classified as
(1) definite diagnosis of Covid-19 disease (def-sympt-Covid-
19): presence of symptomatic Covid-19 infection always
confirmed by positive oral/nasopharyngeal swabs at po-
lymerase chain reaction testing;
(2) highly suspected Covid-19 disease (suspect-sympt-
Covid-19): presence of fever (temperature > 99 °F)
and/or known contact with Covid-19-infected individu-
al, plus four or more symptoms, such as dry cough, sore
throat, shortness of breath, dyspnea, sudden worsening
of preexisting respiratory symptoms, anosmia,
dysgeusia, nausea, vomiting, headache, diarrhea. This
group comprises a significant number of patients char-
acterized by manifestations highly suggestive of Covid-
19 disease not confirmed by Covid-19 oral /
nasopharyngeal swabs at polymerase chain reaction test-
ing (because they were not submitted to the test, often
due to limited availability of virological tests).
The results were analyzed performing the odds ratio (OR)
by Java-Stat 2-way Contingency Table Analysis. STATA,
and StatView were also used to evaluate other variables (data
are expressed as mean ± 2SD).
Shapiro-Wilk test was used to evaluate the distribution of
age and disease duration.
Results
Main demographic and clinical features of the 1641 ASD
Italian patients examined in this survey study are reported in
Table 1. The ASD series encompasses 938 patients with “in-
flammatory arthritis” (rheumatoid arthritis, psoriatic arthritis,
ankylosing spondylitis), 615 patients with “connective tissue
diseases” [systemic sclerosis (SSc), systemic lupus, undiffer-
entiated connective tissue disease, polymyositis/dermatomyo-
sitis, Sjogren’s syndrome], and miscellany of 88 subjects with
less frequent ASD. The female/male ratio (3.26:1) of the
whole series confirmed the well-known prevalence of female
gender commonly observed in ASD, especially in connective
tissue diseases.
With respect to ongoing treatments, the large majority of
patients (95%) were taking at least one of the major anti-
rheumatic immune-modifier drugs, namely, conventional syn-
thetic disease-modifying anti-rheumatic drugs (csDMARD),
biological disease-modifying anti-rheumatic drugs
(bDMARD), and targeted synthetic disease-modifying anti-
rheumatic drugs (tsDMARD). Patients with “connective tis-
sue diseases” were more often treated with mycophenolate
mofetil, methotrexate, some bDMARD (rituximab and beli-
mumab), and/or vasoactive drugs [the latter more frequently
employed in SSc patients] (Table 1), than patients with “in-
flammatory arthritis”.
Following the proposed classification criteria, def-sympt-
Covid-19 was recorded in 11 (0.7%) and suspect-sympt-
Covid-19 in 14 (0.8%) ASD patients; on the whole 25 patients
with def-sympt-Covid-19, or suspect-sympt-Covid-19, were
present among ASD patients (1.5%). This prevalence was
higher than that observed in the Italian population of Covid-
19-infected individuals [349/100,000 = 0.3%; data from the
Italian Superior Institute of Health (ISS)] [17].
A lower mean age and a higher prevalence of female gen-
der were observed in the ASD population with respect to the
Italian Covid-19-infected population (60 vs 62 years; 76% vs
53%, respectively) [17].Clinically, mild-moderate Covid-19
syndrome was observed in 23 ASD patients without differ-
ences between def-sympt-Covid-19 or suspect-sympt-Covid-
19. Two patients developed severe Covid-19 disease, namely:
(1) a 74-year-old female with inflammatory arthritis associat-
ed to Schnitzler’s syndrome developed def-sympt-Covid-19
needing hospitalization for severe pneumonia, who recovered
within a 3-week period; (2) a 65-year-old female with SSc
(and lung fibrosis) with def-sympt-Covid-19, who died for
severe acute respiratory distress syndrome, pulmonary
venous/arterial thrombotic disease, and embolic stroke.
On the whole, significant higher prevalence of def-sympt-
Covid-19 was observed in patients resident in the two regions
of north-central Italy (Emilia Romagna and Tuscany), com-
pared to southern Italy (Calabria) (p = .000).
Table 2 shows the prevalence of def-sympt-Covid-19 or
suspect-sympt-Covid-19, observed in the ASD series com-
pared to the prevalence of Covid-19 infection in the Italian,
or regional, general population [17]. A significantly (p = .030)
higher prevalence of def-sympt-Covid-19 was observed in the
whole ASD series, compared to the Italian general population;
similarly, a significantly higher prevalence was observed for
either suspect-sympt-Covid-19 (p < .001) or when adding def-
sympt-Covid-19 with suspect-sympt-Covid-19 (p = .001, and
p = .000, respectively).
The prevalence of Covid-19 recorded in ASD patients res-
ident in the three Italian regions considered in our survey was
also matched with that reported in the corresponding regional
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general populations [17]. A significantly higher prevalence
was observed for def-sympt-Covid-19 in ASD patient sub-
groups resident in Tuscany (p = .000) and Calabria
(p = .001) (with respect to the regional population), but not
for Emilia Romagna (this last result likely due to the lower
number of recruited patients in this region, and the frequent
unavailability of swab test). A significantly higher prevalence
was found for suspect-sympt-Covid-19 in ASD from Emilia
Romagna (p = .000) or Calabria (p = .042). However, the
prevalence of the def-sympt-Covid-19 + suspect-sympt-
Covid-19 patients was significantly increased in each of the
above mentioned regions in ASD patients (p < .000, for each
comparison).
The comparison of Covid-19 infection, among the sub-
groups of ASD patients according to diagnosis (“connective
tissue diseases” vs “inflammatory arthritis”), or absence/
presence of major comorbidities, or different treatment cate-
gories, revealed some significant differences (Table 3):
(a) the group of patients with “connective tissue diseases”
showed higher prevalence of either suspect-sympt-
Covid-19 (p < .000) or def-sympt-Covid-19 + suspect-
sympt-Covid-19 (p < .000), compared to the complex of
“inflammatory arthritis”;
(b) the prevalence of def-sympt-Covid-19was higher in ASD
without major comorbidities (p = .015);
(c) patients without csDMARD revealed significantly higher
prevalence of either suspect-sympt-Covid-19 (p = .003)
or def-sympt-Covid-19 + suspect-sympt-Covid-19
(p = .011).
Discussion
The present survey study investigated the prevalence of
Covid-19 in a large ASD patient series from three distinct
regions of Italy characterized by different pandemic spread.
A significantly higher prevalence of def-sympt-Covid-19 was
observed both in the whole ASD population (with respect to
the Italian general population) and in the regional ASD sub-
groups of Tuscany, or Calabria, patients (when compared with
the corresponding regional prevalence of Covid-19). The rel-
atively low prevalence of def-sympt-Covid-19 in the Emilia
Romagna might be probably associated with the lower num-
ber of ASD patients evaluated in this region compared to those
from Tuscany and Calabria, and the frequent unavailability of
swab test. These significant differences are reinforced by the
consideration that we have compared the prevalence of symp-
tomatic Covid-19 ASD patients, with that of Covid-19-
infected patients from the general population, that comprises
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evaluation) [17]. In addition, the majority of subjects screened
for Covid-19 were among those with high risk of infection
such as health professionals. So, the differences might be
more pronounced if a swab test screening would have been
performed in ASD patients.
Significant differences were also found in both ASD pa-
tients with suspect-sympt-Covid-19 and in the entire group of
def-sympt-Covid-19+suspect-sympt-Covid-19 ASD. Patients
with suspect-sympt-Covid-19 are characterized by a number
of signs and symptoms highly suggestive of Covid-19; there-
fore, they should be clinically considered, at least provision-
ally, as true Covid-19 even in the absence of oral/
nasopharyngeal swabs due to limited availability of virologi-
cal tests at the time of the survey.
This assumption is also suggested by the observation of
two patients previously classified as suspect-sympt-Covid-
19, who subsequently revealed positive at swab testing during
the survey period and were therefore classified as def-sympt-
Covid-19.
Of note, the patients’ awareness of the risks inherent in
their chronic illness along with the frequent physical limita-
tions, all together, may lead to very cautious patients’ lifestyle,
that in the case of the ongoing pandemic has certainly reduced
the risk of contracting Covid-19 measures aimed at slowing
the spread of the virus. However, the statistically increased
prevalence of Covid-19 observed in our large series of patients
with ASD certainly related to the increased susceptibility to
infections has been favored by the high exposure to the virus
during the frequent contacts with medical facilities and/or
hospitalizations before the restriction measures on individual
movement.
The higher prevalence of Covid-19 in ASD compared to
that found in Italian general population was further empha-
sized by some demographic observations; in particular, ASD
patients showed lower mean age, as well as a higher percent-
age of females. These findings are in counter tendency with
respect to the epidemiology of Covid-19 symptomatic pa-
tients, which are prevalently male, aged > 60 years.
Accordingly to the different diffusion of Covid-19 in the
Italian territory with a clear-cut north-south gradient, the ASD
patients of north-central Italian macro-area (Emilia Romagna
+ Tuscany) showed higher prevalence of Covid-19 than those
of southern Italy (Calabria).
Previous clinical investigations focusing on patients with
various ASD complicated by Covid-19 reported in the world
literature are summarized in Table 4 [18–33]; they include 4
single case observations [18–21], 3 cohort studies [22–25], a
population-based study [32], and 6 survey studies [26–31, 33].
Overall, these previous reports indicated a prevalence of
Covid-19 frequently comparable with those observed in the
general population of corresponding geographical areas, par-
ticularly for patients series with chronic arthritis [26, 27],
while increased percentage of Covid-19 affected patients with
connective tissue diseases, namely systemic lupus [28] or
large vessel vasculitis [29]. In all cases, the ongoing
immune-modifier treatments, especially bDMARD, did not
affect the outcomes of symptomatic, generally mild Covid-
19 disease.
Of note, the statistical analysis revealed a higher prevalence
of Covid-19 in the group of patients with “connective tissue
diseases”, when compared with patients affected by different
“inflammatory arthritis”, possibly due to more pronounced
immune system dysfunction present in the first patients’
group; in agreement with the increased prevalence of Covid-
19 observed in a series of patients with systemic lupus [28], or
large vessel vasculitis [29].
Another interesting finding was the higher prevalence of
Covid-19 in ASD without concomitant comorbidities; this
unexpected observation may deserve further investigations,
and however reinforce the concept that the immune-
dysfunction is the main reason of the higher prevalence of
Covid-19 infection in ASD patients.
Similarly, it is very difficult to explain the increased prev-
alence of Covid-19 in patient without ongoing csDMARD
treatments; tentatively, we can hypothesize some protective
role of long-term administration of any of these medications
(perhaps, hydroxyl-chloroquine) towards Covid-19 infection,
while presence/absence of other immune-modulating drugs,
mainly bDMARD and tsDMARD, seems to be not relevant
for the development/outcome of Covid-19, in agreement with
data reported in previous studies (Table 4).
Overall, the results of the present survey including a wide
spectrum of ASD, i.e., “connective tissue diseases”, and “in-
flammatory arthritis”, seem to confirm the relatively benign
outcomes of Covid-19 in patients with ASD [23–31], consid-
ering that only one patient with SSc complicated by lung
fibrosis died among 25 subjects with def-sympt-Covid-19 or
suspect-sympt-Covid-19. However, the increased prevalence
of Covid-19 in ASD is in keeping with the well-known sus-
ceptibility of immune-compromised patients towards all in-
fectious pathogens. Covid-19 is still scarcely known as
regards the pathogenesis and clinical course of acute manifes-
tations. Moreover, the few data available to now, as regards
both pathological and immunological changes, are insufficient
to predict the long-term effects of the infection, particularly for
patients with profound immune system dysfunction such as
ASD. In this respect, some manifestations of severe Covid-19
are comparable to that detectable in many ASD; in particular,
the interstitial lung and diffuse vascular injury, that although
evolving more quickly in severe Covid-19 disease, seems to
reproduce the main pathological alterations of SSc [34, 35].
Our study may present some limitations, mainly with
regards to the modality of patients’ data recording and the lack
of proper virological testing in patients with highly suspected
Covid-19. The limitations inherent to telemedicine, largely
used during the pandemic restrictions on individual mobility,
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might be balanced at least in part by the good compliance of
patients, interviewed by the same physicians who normally
followed them in the face-to-face outpatient visits. While the
classification of Covid-19 as highly suspected, on the basis of
clear-cut clinical symptoms, should be confirmed by patients’
follow-up study with validated antibody tests able to detected
previous exposure to Covid-19.
In conclusion, the finding of a higher prevalence of Covid-
19 in immune-compromised ASD patients is particularly chal-
lenging for at least two aspects: (a) firstly, it suggests the need
to develop valuable prevention and management strategies for
ASD patients particularly vulnerable during the ongoing
Covid-19 pandemic or its possible re-exacerbation; (b) it stim-
ulates in-depth investigations to verify the potential interac-
tions between Covid-19 infection and impaired immune sys-
tem of ASD that may affect the natural course of both
disorders.
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